Growth hormone deficiency epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
* The incidence of persistent GHD was 12.0%. <ref name="pmid25301482">{{cite journal| author=Smyczyńska J, Stawerska R, Lewiński A, Hilczer M| title=Incidence and predictors of persistent growth hormone deficiency (GHD) in patients with isolated, childhood-onset GHD. | journal=Endokrynol Pol | year= 2014 | volume= 65 | issue= 5 | pages= 334-41 | pmid=25301482 | doi=10.5603/EP.2014.0046 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25301482 }}</ref> | |||
* There is no significant difference in the incidence of pituitary hypoplasia between the patients with persistent and transient GHD. | |||
==== Sex ==== | ==== Sex ==== | ||
Revision as of 16:10, 17 August 2017
|
Growth hormone deficiency Microchapters |
|
Differentiating Growth hormone deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Growth hormone deficiency epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Growth hormone deficiency epidemiology and demographics |
|
FDA on Growth hormone deficiency epidemiology and demographics |
|
CDC on Growth hormone deficiency epidemiology and demographics |
|
Growth hormone deficiency epidemiology and demographics in the news |
|
Blogs on Growth hormone deficiency epidemiology and demographics |
|
Risk calculators and risk factors for Growth hormone deficiency epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Epidemiology and Demographics
Incidence
- The incidence of persistent GHD was 12.0%. [1]
- There is no significant difference in the incidence of pituitary hypoplasia between the patients with persistent and transient GHD.
Sex
- The sex distribution of patients with idiopathic growth hormone deficiency is 73% male and 27% female.
- Cuttler et al published results of a survey of pediatric endocrinologists that growth hormone treatment was 1.3 times more common in boys than in girls.
Age
- Diagnosis of growth hormone deficiency is made during 2 broad age peaks; the first age peak occurs at 5 years, a time when children begin school. The second age peak occurs in girls aged 10-13 years and boys aged 12-16 years.
- While congenital GHD and most cases of idiopathic GHD are thought to be present from birth, diagnosis is often delayed until the patient’s short stature is noticed in relation to their peers.
Race
- There is no apparent racial difference in the incidence of GHD.
Gender
- Growth hormone deficiency affects males and females equally.
- However, due to societies that care a lot about males short stature than the females, seventy-three percent of patients with idiopathic GHD in were males
- Patients with GHD from organic causes such as tumors and radiation, in which no gender bias should be present, were still 62% male.
References
- ↑ Smyczyńska J, Stawerska R, Lewiński A, Hilczer M (2014). "Incidence and predictors of persistent growth hormone deficiency (GHD) in patients with isolated, childhood-onset GHD". Endokrynol Pol. 65 (5): 334–41. doi:10.5603/EP.2014.0046. PMID 25301482.